Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free CINGW Stock Alerts

Cingulate (CINGW) Competitors

$0.0069 0.00 (-13.70%)
As of 09/11/2026 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CINGW vs. SXTPW, BFRIW, CLVR, CMRAW, and CDTTW

Should you buy Cingulate stock or one of its competitors? Cingulate's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Clever Leaves (CLVR), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cingulate compare to 60 Degrees Pharmaceuticals?

Cingulate (NASDAQ:CINGW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

In the previous week, Cingulate and Cingulate both had 2 articles in the media. Cingulate's average media sentiment score of 1.43 beat 60 Degrees Pharmaceuticals' score of 0.44 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
60 Degrees Pharmaceuticals Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Summary

Cingulate and 60 Degrees Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

How does Cingulate compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Biofrontera and Biofrontera both had 2 articles in the media. Cingulate's average media sentiment score of 1.43 beat Biofrontera's score of 0.44 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Cingulate Positive

Summary

Biofrontera and Cingulate tied by winning 1 of the 2 factors compared between the two stocks.

How does Cingulate compare to Clever Leaves?

Cingulate (NASDAQ:CINGW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cingulate has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

In the previous week, Cingulate had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Clever Leaves. Cingulate's average media sentiment score of 1.43 beat Clever Leaves' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Clever Leaves Neutral

Summary

Clever Leaves beats Cingulate on 3 of the 5 factors compared between the two stocks.

How does Cingulate compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Comera Life Sciences. Cingulate's average media sentiment score of 1.43 beat Comera Life Sciences' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Cingulate beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

How does Cingulate compare to Conduit Pharmaceuticals?

Cingulate (NASDAQ:CINGW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.89 beat Cingulate's score of 1.43 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Positive
Conduit Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Cingulate and Conduit Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CINGW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CINGW vs. The Competition

Export
MetricCingulatePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.41B$7.16B$12.85B
Dividend YieldN/A2.64%2.57%11.17%
P/E RatioN/A799.75274.9425.36
Price / SalesN/A966.93686.57116.78
Price / CashN/A88.1776.6551.52
Price / BookN/A10.3910.336.20
Net IncomeN/A$2.85B$3.50B$358.50M
7 Day PerformanceN/A-3.61%-3.32%-2.35%
1 Month PerformanceN/A0.72%-0.53%-3.23%
1 Year PerformanceN/A3.61%23.51%8.79%

Cingulate Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CINGW
Cingulate
N/A$0.01
-13.7%		N/A-86.9%$0.00N/AN/A20
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-30.1%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
+3.0%		N/A-81.5%$0.00$46.18MN/A70
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CINGW) was last updated on 9/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel